Clinical Trial

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: * To what extent does minocycline lower blood pressure? * Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-01-30; most recent amendment 2026-03-05.
Status change: Not Yet Recruiting → Recruiting 2024-12-09
Trial Details
NCT Number NCT06246396
Lead Sponsor University of Florida
Collaborators: Emory University, National Heart, Lung, and Blood Institute (NHLBI)
Conditions Hypertension, Resistant to Conventional Therapy
Enrollment 120 participants
Start Date 2025-01-08
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2026-03-06